Literature DB >> 18397703

Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine.

C Bartel1, N Obermüller, M J Rummel, H Geiger, I A Hauser.   

Abstract

In a 56-year-old white male patient, a membranoproliferative glomerulonephritis Type I was diagnosed after a 12-month history of low grade B cell lymphoma (Binet A). HIV, Hepatitis B and C serology were negative. Due to an impairment of renal function despite chemotherapy with COP, an immunochemotherapy consisting of rituximab (6 cycles) and bendamustine (4 cycles) was given. This therapeutic approach caused a complete remission of the nephrotic syndrome. Renal function and arterial hypertension improved markedly. In addition, urinary sediment became normal and proteinuria disappeared completely.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397703     DOI: 10.5414/cnp69285

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

1.  A rare case of atypical chronic lymphocytic leukaemia presenting as nephrotic syndrome.

Authors:  Martina Soldarini; Lucia Farina; Augusto Genderini; Niccolo Bolli
Journal:  BMJ Case Rep       Date:  2017-07-14

2.  Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience.

Authors:  Paolo Strati; Samih H Nasr; Nelson Leung; Curtis A Hanson; Kari G Chaffee; Susan M Schwager; Sara J Achenbach; Timothy G Call; Sameer A Parikh; Wei Ding; Neil E Kay; Tait D Shanafelt
Journal:  Haematologica       Date:  2015-06-18       Impact factor: 9.941

Review 3.  Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.

Authors:  Wai Yew Kong; Ramyasuda Swaminathan; Ashley Irish
Journal:  Int Urol Nephrol       Date:  2012-07-15       Impact factor: 2.370

Review 4.  Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.

Authors:  Michael Rudnicki
Journal:  Biomed Res Int       Date:  2017-05-09       Impact factor: 3.411

5.  Rituximab Treatment for PR3-ANCA-Positive Membranoproliferative Glomerulonephritis Associated with Adult-Onset Periodic Fever Syndrome.

Authors:  Yoshitomo Hamano; Hiromichi Yoshizawa; Taro Sugase; Takuya Miki; Naoko Ohtani; Shiho Hanawa; Eri Takeshima; Yoshiyuki Morishita; Osamu Saito; Fumi Takemoto; Shigeaki Muto; Wako Yumura; Eiji Kusano
Journal:  Case Rep Nephrol Urol       Date:  2012-07-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.